Sarepta Therapeutics Inc is a US-based pharmaceutical company with a medium risk rating score of 29.9. Specializing in treating rare and infectious diseases, Sarepta uses ESG principles in the rapid development of its drug candidates. By leveraging proprietary RNA-targeted technology platforms, the company aims to address key medical needs and develop novel pharmaceutical products. Sarepta outsources manufacturing to third-party contractors and focuses on early-stage product candidate development.